159 related articles for article (PubMed ID: 3367184)
1. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
[TBL] [Abstract][Full Text] [Related]
2. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
Thiébaud D; Portmann L; Jaeger P; Jacquet AF; Burckhardt P
Bone; 1986; 7(4):247-53. PubMed ID: 3768203
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of neoplastic hypercalcemia using single-infusion diphosphonate].
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
Schweiz Med Wochenschr; 1988 Jan; 118(3):77-81. PubMed ID: 3344411
[TBL] [Abstract][Full Text] [Related]
4. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
J Bone Miner Res; 1986 Dec; 1(6):555-62. PubMed ID: 3503561
[TBL] [Abstract][Full Text] [Related]
5. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
Thiébaud D; Jacquet AF; Burckhardt P
Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
[TBL] [Abstract][Full Text] [Related]
6. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
[TBL] [Abstract][Full Text] [Related]
7. Treatment of tumor-induced osteolysis by APD.
Burckhardt P; Thiébaud D; Perey L; von Fliedner V
Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
[TBL] [Abstract][Full Text] [Related]
8. Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone.
Thiebaud D; Jaeger P; Burckhardt P
J Bone Miner Res; 1990 Mar; 5(3):221-6. PubMed ID: 2333780
[TBL] [Abstract][Full Text] [Related]
9. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
10. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
11. Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate.
Boudailliez BR; Pautard BJ; Sebert JL; Kremp O; Piussan CX
Pediatr Nephrol; 1990 Sep; 4(5):510-1. PubMed ID: 2242318
[TBL] [Abstract][Full Text] [Related]
12. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
[TBL] [Abstract][Full Text] [Related]
13. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
14. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
15. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
[TBL] [Abstract][Full Text] [Related]
16. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
Yates AJ; Murray RM; Jerums GJ; Martin TJ
Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
[TBL] [Abstract][Full Text] [Related]
17. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
Endo K; Katsumata K; Iguchi H; Kubodera N; Teramoto T; Ikeda K; Fujita T; Ogata E
J Bone Miner Res; 1998 Sep; 13(9):1378-83. PubMed ID: 9738509
[TBL] [Abstract][Full Text] [Related]
18. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Mannix KA; Carmichael J; Harris AL; Cantwell BM
Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
[TBL] [Abstract][Full Text] [Related]
19. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
Davis JR; Heath DA
Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920
[TBL] [Abstract][Full Text] [Related]
20. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]